Andressa de Souza

Andressa de Souza

Auto-generated profile, based on publicly available information

Andressa de Souza

Universidade Federal do Rio Grande do Sul

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Frontiers in Psychiatry
Verified
Journal Article
Open access
LMLiciane Fernandes Medeiros
Liciane Fernandes Medeiros
ISIzabel Cristina Custódio de Souza
Izabel Cristina Custódio de Souza
LVLiliane Pinto Vidor
Liliane Pinto Vidor
ASAndressa de Souza
Andressa de Souza
ADAlícia Deitos
Alícia Deitos
Iraci L.S. TorresIraci L.S. Torres
Iraci L.S. Torres
Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation technique that is affordable and easy to operate compared to other neuromodulation techniques. Anodal stimulation increases cortical excitability, while the cathodal stimulation decreases it. Although tDCS is a promising treatment approach for chronic pain as well as for neuropsychiatric diseases and other neurological disorders, several complex neurobiological mechanisms that are not well understood are involved in its effect. The purpose of this systematic review is to summarise the current knowledge regarding the neurobiological mechanisms involved in the effects of tDCS. The initial search resulted in 171 articles. After applying inclusion and exclusion criteria, we screened 56 full text papers to extract findings about the neurobiology of tDCS effects including investigation of cortical excitability parameters. Overall, these findings show that tDCS involves a cascade of events at the cellular and molecular levels. Moreover, tDCS involves glutamatergic, GABAergic, dopaminergic, serotonergic and cholinergic neurotransmitter function. However, further studies that aim to understand the basic and clinical neuroscience of tDCS are needed to improve our understanding on its entire mechanism of action and to also its impact in the clinical setting.

1 September 2017 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
WCWolnei Caumo
Wolnei Caumo
LALuciana C. Antunes
Luciana C. Antunes
JEJéssica Lorenzzi Elkfury
Jéssica Lorenzzi Elkfury
EHEvelyn G Herbstrith
Evelyn G Herbstrith
RSRaquel Busanello Sipmann
Raquel Busanello Sipmann
RNRandy Neblett
Randy Neblett
Objectives: The primary aim was to assess the psychometric properties (including internal consistency, construct validity, reproducibility, and factor structure) of the Central Sensitization Inventory (CSI), adapted and validated for a Brazilian population (CSI-BP). Additionally, we evaluated the relationship between the CSI-BP and the serum brain-derived neurotrophic factor (BDNF) and determined if the symptoms elicited by the CSI-BP discriminate between subjects who do/do not respond to the conditioned pain modulation (CPM) task, as assessed by change in numeric pain scale (0–10) score. Patients and methods: A cross-sectional study was conducted in a pain clinic in a tertiary teaching hospital. A total of 222 adults with chronic musculoskeletal pain and 63 healthy control subjects completed the CSI-BP and the Brazilian Portuguese pain-catastrophizing scale (BP-PCS). A team of experts translated the CSI according to the international guidelines. Test–retest, item analysis, convergent validity, and factor analysis were performed. Later, a random subsample (n=77) was used to correlate the CSI-BP adjusted index with change in numeric pain-scale score during the CPM task and a BDNF blood sample. Results: The CSI-BP presented strong psychometric properties (test–retest reliability 0.91, Cronbach’s a=0.91). Confirmatory factor analysis yielded a four-factor structure, supporting the original English version. The CSI-BP adjusted index showed moderate positive correlation with the BP-PCS, and classified more than 80% of patients correctly vs healthy controls. Serum BDNF levels explained 27% of the variation in the CSI-BP adjusted index. Subjects with impairment in the descending modulatory system had higher CSI-BP adjusted index scores than subjects who responded normally to the CPM task: 49.35 (12.1) vs 39.5 (12.33), respectively (P<0.05). Conclusion: The CSI-BP was found to be a psychometrically strong and reliable instrument, with primary evidence of validity. Higher scores on the CSI-BP were correlated positively with serum BDNF and with greater dysfunction of the descending pain-modulatory system.

1 June 2013 in Pain
Verified
Journal Article
Closed access
ASAndré Schwertner
André Schwertner
CSClaudia C. Conceição dos Santos
Claudia C. Conceição dos Santos
GCGislene Dalferth Costa
Gislene Dalferth Costa
ADAlícia Deitos
Alícia Deitos
ASAndressa de Souza
Andressa de Souza
WCWolnei Caumo
Wolnei Caumo
Endometriosis-associated chronic pelvic pain (EACPP) presents with an intense inflammatory reaction. Melatonin has emerged as an important analgesic, antioxidant, and antiinflammatory agent. This trial investigates the effects of melatonin compared with a placebo on EACPP, brain-derived neurotrophic factor (BDNF) level, and sleep quality. Forty females, aged 18 to 45 years, were randomized into the placebo (n = 20) or melatonin (10 mg) (n = 20) treatment groups for a period of 8 weeks. There was a significant interaction (time vs group) regarding the main outcomes of the pain scores as indexed by the visual analogue scale on daily pain, dysmenorrhea, dysuria, and dyschezia (analysis of variance, P < 0.01 for all analyses). Post hoc analysis showed that compared with placebo, the treatment reduced daily pain scores by 39.80% (95% confidence interval [CI] 12.88-43.01%) and dysmenorrhea by 38.01% (95% CI 15.96-49.15%). Melatonin improved sleep quality, reduced the risk of using an analgesic by 80%, and reduced BNDF levels independently of its effect on pain. This study provides additional evidence regarding the analgesic effects of melatonin on EACPP and melatonin's ability to improve sleep quality. Additionally, the study revealed that melatonin modulates the secretion of BDNF and pain through distinct mechanisms.

1 August 2014 in The Journal of Pain
Verified
Journal Article
Closed access
LDLetizzia Dall’aGnol
Letizzia Dall’aGnol
LMLiciane Fernandes Medeiros
Liciane Fernandes Medeiros
Iraci L.S. TorresIraci L.S. Torres
Iraci L.S. Torres
ADAlicia Deitos
Alicia Deitos
ABAline Brietzke
Aline Brietzke
WCWolnei Caumo
Wolnei Caumo

15 July 2016 in Frontiers in Human Neuroscience
Verified
Journal Article
Open access
WCWolnei Caumo
Wolnei Caumo
ADAlícia Deitos
Alícia Deitos
Sandra CarvalhoSandra Carvalho
Sandra Carvalho
Jorge LeiteJorge Leite
Jorge Leite
FCFabiana Carvalho
Fabiana Carvalho
Felipe FregniFelipe Fregni
Felipe Fregni
The central sensitization syndrome (CSS) encompasses disorders with overlapping symptoms in a structural pathology spectrum ranging from persistent nociception [e.g., osteoarthritis (OA)] to an absence of tissue injuries such as the one presented in fibromyalgia (FM) and myofascial pain syndrome (MPS). First, we hypothesized that these syndromes present differences in their cortical excitability parameters assessed by TMS, namely motor evoked potential (MEP), cortical silent period (CSP), short intracortical inhibition (SICI) and short intracortical facilitation (SICF). Second, considering that the presence of tissue injury could be detected by serum neurotrophins, we hypothesized that the spectrum of structural pathology (i.e., from persistent nociception like in OA, to the absence of tissue injury like in FM and MPS), could be detected by differential efficiency of their descending pain inhibitory system, as assessed by the conditioned pain modulation (CPM) paradigm. Third, we explored whether BDNF had an influence on the relationship between motor cortex excitability and structural pathology. This cross-sectional study pooled baseline data from three randomized clinical trials. We included females (n=114), aged 19 to 65 years old with disability by chronic pain syndromes: FM (n= 19), MPS (n=54), OA (n=27) and healthy subjects (n=14). We assessed the serum BDNF, the motor cortex excitability by parameters the TMS measures and the change on Numerical Pain Scale [NPS (0-10)] during CPM-task. The adjusted mean (SD) on the SICI observed in the absence of tissue injury was 56.36% lower than with persistent nociceptive input [0.31(0.18) vs. 0.55 (0.32)], respectively. The BDNF was inversely correlated with the SICI and with the change on NPS (0-10) during CPM-task. These findings suggest greater disinhibition in the motor cortex and the descending pain inhibitory system in FM and MPS than in OA and healthy subjects. Likewise, the inter-hemispheric disinhibition as well the dysfunction in the descending pain modulatory system is higher in chronic pain without tissue injury compared to a structural lesion. In addition, they highlight that a greater level of serum BDNF mediated the disinhibition of motor cortex excitability, as well the function of descending inhibitory pain modulation system, independently of the physiopathology mechanism of musculoskeletal pain syndromes.

1 December 2012 in Brain Research
Verified
Journal Article
Closed access
LALauren Naomi Spezia Adachi
Lauren Naomi Spezia Adachi
WCWolnei Caumo
Wolnei Caumo
GLGabriela Laste
Gabriela Laste
LMLiciane Fernandes Medeiros
Liciane Fernandes Medeiros
JRJoanna Ripoll Rozisky
Joanna Ripoll Rozisky
Iraci L.S. TorresIraci L.S. Torres
Iraci L.S. Torres